<DOC>
	<DOCNO>NCT00102336</DOCNO>
	<brief_summary>The purpose study evaluate efficacy AMG 531 treatment thrombocytopenia subject ITP measure platelet response . This study also evaluate change Patient Reported Outcomes Health Resource Utilization due treatment AMG 531 .</brief_summary>
	<brief_title>AMG 531 Treatment Thrombocytopenic Subjects With Immune ( Idiopathic ) Thrombocytopenic Purpura ( ITP ) Prior Splenectomy</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Diagnosis ITP accord American Society Hematology ( ASH ) guideline ( Appendix F ) Have complete least 1 prior treatment ITP ( e.g. , prednisone ) Subjects great 60 year age must document history chronic ITP bone marrow report confirm diagnosis The platelet count ( calculate mean 2 count take screen pretreatment period ) must : *less 30 x 10^9/L subject receive ITP therapy , count great 35 x 10^9/L *less 50 x 10^9/L subject receive constant dose schedule corticosteroid , azathioprine danazol count great 55 x 10^9/L A serum creatinine concentration less equal 2 mg/dl ( less equal 176.8 Âµmol/L ) Adequate liver function , evidence serum bilirubin less equal 1.5 time laboratory normal range Hemoglobin great 11.0 g/dL Written inform consent ( see Section 12.1 ) Have Splenectomy reason Any known history bone marrow stem cell disorder ( Any abnormal bone marrow finding typical ITP must approve Amgen subject may enrol study ) Any active malignancy . If prior history cancer basal cell carcinoma cervical carcinoma situ , treatment active disease within 5 year randomization Documented diagnosis arterial thrombosis ( i.e. , stroke , transient ischemic attack myocardial infarction ) past year History venous thrombosis ( i.e. , deep vein thrombosis , pulmonary embolism ) include subject antcoagulation therapy Unstable uncontrolled disease condition relate impacting cardiac function ( e.g. , unstable angina , congestive heart failure [ NYHA great class II ] , uncontrolled hypertension [ diastolic great 100 mmHg ] cardiac arrhythmia ) Have 3 follow predispose factor thromboembolic event : diabetes ; smoker ; use oral contraceptive ; estrogen therapy ; know positive antiphospholipid antibody ; hypertriglyceridemia ; hypercholesteremia ( great 240 mg/dL ) ; treatment hypertension Known positive test human immunodeficiency virus ( HIV ) infection hepatitis C virus Currently receive treatment ITP except corticosteroid , azathioprine danazol administer constant dose schedule IV Ig antiD Ig within 2 week screen visit Rituximab ( indication ) within 14 week screen visit anticipate use time propose study Received hematopoietic growth factor , include IL11 ( oprelvekin ) within 4 week screen visit Past present participation study evaluate PEGrHuMGDF , recombinant human thrombopoietin ( rHuTPO ) , AMG 531 related platelet product Received aklylating agent within 8 week screen visit anticipate use time propose study Less 4 week since receipt therapeutic drug device FDA approve indication screen period Less 8 week since major surgery Pregnant breast feeding Subjects reproductive potential use adequate contraceptive precaution , judgment investigator Known hypersensitivity recombinant E coliderived product Concerns subject 's compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>immune ( idiopathic ) thrombocytopenic purpura</keyword>
	<keyword>pre-splenectomy</keyword>
	<keyword>ITP</keyword>
	<keyword>Thrombopenia</keyword>
</DOC>